All In Biotech

Drug Trial Radar · NCT07017946

Intestinal Microbiome Transplant in ALS

A Pilot Trial to Investigate the Safety and Efficacy of Intestinal Microbiome Transplant (MTT) in People With Amyotrophic Lateral Sclerosis

Last checked: Nov 20, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Jan 27, 2026

Primary completion

Nov 1, 2026

Study completion Nov 1, 2026

Sponsor

Lead sponsor
Duke UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Minnesota
First posted
Jun 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 24-week study of intestinal microbiome transplant in people with ALS. All participants will be evaluated clinically in person for 4 visits. Blood and mailed/ fresh stool samples will also be collected. Blood samples will be used to determine changes in neurofilament light chain over time. Stool samples will be processed for microbiome analysis. Participants will have phone visits to further evaluate safety and tolerability. They will then undergo antibiotic conditioning and a standard bowel preparation before being assigned to the investigational product, MTP-101C .

Conditions

  • Amyotrophic Lateral Sclerosis ALS

Interventions

  • MTP-101CDrug

    MTP-101C is a freeze-dried encapsulated formulation of fecal microbiota purified from the stool of healthy donors.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ALS Functional Rating Scale, Revised (ALSFRS-R)Time frame: Weeks 0, 4, 8, 12, 16, 20 and 24
  2. ALS Quality of Life (ALSAQ-5)Time frame: Weeks 0, 4, 12, and 24
  3. Neurofilament Light Chain levelsTime frame: Weeks 0, 4, 12 and 24
  4. The Gastrointestinal Symptom Rating Scale (GSRS)Time frame: Weeks 0, 4, 12, and 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Duke University Medical Center

    Durham, North Carolina · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.